PURPOSE: Information regarding the treatment of pleural lavage cytology (PLC)-positive patients is still limited. This study evaluated the efficacy of intrapleural chemotherapy (IPC) in PLC-positive patients. METHODS: Three hundred eighty-six of the 567 lung cancer patients who underwent surgery had undergone PLC after thoracotomy, following by a complete resection were evaluated. IPC was performed after surgery, and cisplatin or adriamycin was injected intrapleurally through the thoracic tube. RESULTS: The pathological diagnosis showed that 17 patients (4.4 %) were positive for (or suspected to have) malignancy in their PLC. The univariate and multivariate analysis showed that only pleural invasion was a significant predictor of a PLC-positive status. The 5-year overall survival in PLC-positive patients was 38 % and that in PLC-negative patients was 84 %. Both the univariate (p < 0.01) and multivariate (p = 0.045) analyses showed that the status of PLC was significantly associated with the overall survival. Eight of the 17 PLC-positive patients underwent IPC. The 2-year OS rate in the patients treated with IPC was 88 % and that of those without IPC was 44 (p = 0.04). CONCLUSION: IPC improved the postoperative survival in PLC-positive NSCLC patients, and a further prospective evaluation regarding this therapy is warranted.
PURPOSE: Information regarding the treatment of pleural lavage cytology (PLC)-positive patients is still limited. This study evaluated the efficacy of intrapleural chemotherapy (IPC) in PLC-positive patients. METHODS: Three hundred eighty-six of the 567 lung cancerpatients who underwent surgery had undergone PLC after thoracotomy, following by a complete resection were evaluated. IPC was performed after surgery, and cisplatin or adriamycin was injected intrapleurally through the thoracic tube. RESULTS: The pathological diagnosis showed that 17 patients (4.4 %) were positive for (or suspected to have) malignancy in their PLC. The univariate and multivariate analysis showed that only pleural invasion was a significant predictor of a PLC-positive status. The 5-year overall survival in PLC-positive patients was 38 % and that in PLC-negative patients was 84 %. Both the univariate (p < 0.01) and multivariate (p = 0.045) analyses showed that the status of PLC was significantly associated with the overall survival. Eight of the 17 PLC-positive patients underwent IPC. The 2-year OS rate in the patients treated with IPC was 88 % and that of those without IPC was 44 (p = 0.04). CONCLUSION: IPC improved the postoperative survival in PLC-positive NSCLCpatients, and a further prospective evaluation regarding this therapy is warranted.
Authors: William Checkley; Keith P West; Robert A Wise; Matthew R Baldwin; Lee Wu; Steven C LeClerq; Parul Christian; Joanne Katz; James M Tielsch; Subarna Khatry; Alfred Sommer Journal: N Engl J Med Date: 2010-05-13 Impact factor: 91.245
Authors: Eric Lim; Ayyaz Ali; Panagiotis Theodorou; Andrew G Nicholson; George Ladas; Peter Goldstraw Journal: J Thorac Cardiovasc Surg Date: 2004-04 Impact factor: 5.209
Authors: H Kondo; H Asamura; K Suemasu; T Goya; R Tsuchiya; T Naruke; K Yamagishi; Y Uei Journal: J Thorac Cardiovasc Surg Date: 1993-12 Impact factor: 5.209
Authors: Yao An Shen; Ing Luen Shyu; Maggie Lu; Chun Lin He; Yen Mei Hsu; Hsiang Fa Liang; Chih Peng Liu; Ren Shyan Liu; Biing Jiun Shen; Yau Huei Wei; Chi Mu Chuang Journal: Int J Nanomedicine Date: 2015-03-30